prikaz prve stranice dokumenta Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
  Download
PDF 7.88 MB
Scientific paper - Original scientific paper
Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
Vaccines, 10 (2022), 2; 153. https://doi.org/10.3390/vaccines10020153
Đaković Rode, Oktavija; Bodulić, Kristian; Zember, Sanja; Cetinić Balent, Nataša; Novokmet, Anđa; Čulo, Marija; Rašić, Željka; Mikulić, Radojka; Markotić, Alemka

Linked objects
COVID-19 | Virtual collection
Cite this document

Đaković Rode, O., Bodulić, K., Zember, S., Cetinić Balent, N., Novokmet, A., Čulo, M. ... Markotić, A. (2022). Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Vaccines, 10. (2). doi: 10.3390/vaccines10020153

Đaković Rode, Oktavija, et al. "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose." Vaccines, vol. 10, no. 2, 2022. https://doi.org/10.3390/vaccines10020153

Đaković Rode, Oktavija, Kristian Bodulić, Sanja Zember, Nataša Cetinić Balent, Anđa Novokmet, Marija Čulo, Željka Rašić, Radojka Mikulić and Alemka Markotić. "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose." Vaccines 10, no. 2 (2022). https://doi.org/10.3390/vaccines10020153

Đaković Rode, O., et al. (2022) 'Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose', Vaccines, 10(2). doi: 10.3390/vaccines10020153

Đaković Rode O, Bodulić K, Zember S, Cetinić Balent N, Novokmet A, Čulo M, and sur.. Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Vaccines [Internet]. 2022 January 20 [cited 2024 November 11];10(2). doi: 10.3390/vaccines10020153

O. Đaković Rode, et al., "Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose", Vaccines, vol. 10, no. 2, January 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:254996. [Accessed: 11 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
AuthorOktavija Đaković Rode
AuthorKristian Bodulić
AuthorSanja Zember
AuthorNataša Cetinić Balent
AuthorAnđa Novokmet
AuthorMarija Čulo
AuthorŽeljka Rašić
AuthorRadojka Mikulić
AuthorAlemka Markotić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Research on post-vaccination antibody dynamics has become pivotal in estimating COVID-19 vaccine efficacy. We studied anti-SARS-CoV-2 Spike RBD IgG levels in 587 healthcare workers (2038 sera) who completed BNT162b2 vaccination. Average antibody titer 3 weeks after the first dose in COVID-19-naïve participants (median 873.5 AU/mL) was 18-fold higher than the test threshold, with a significant increase 1 month (median 9927.2 AU/mL) and an exponential decrease 3 (median 2976.7 AU/mL) and 6 (median 966.0 AU/mL) months after complete vaccination. Participants with a history of COVID-19 prior to vaccination showed significantly higher antibody levels, particularly after the first dose (median 14,280.2 AU/mL), with a slight decline 1 month (median 12,700.0 AU/mL) and an exponential decline in antibody titers 3 (median 4831.0 AU/mL) and 6 (median 1465.2 AU/mL) months after vaccination. Antibody levels of COVID-19-naïve subjects after the first dose were moderately correlated with age (r = −0.4). Multivariate analysis showed a strong independent correlation between IgG levels 6 months after vaccination and both IgG titers after the first dose and 1 month after vaccination (R2 = 0.709). Regardless of pre-vaccination COVID-19 history, IgG levels 6 months after vaccination were comparable to antibody levels reached by COVID-19-naïve participants after the first vaccine dose.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleVaccines
Numberingvol. 10, no. 2, 153
e-ISSN2076-393X
DOIhttps://doi.org/10.3390/vaccines10020153
URN:NBNurn:nbn:hr:184:254996
Publication2022-01-20
ProjectNumber: KK.011.1.01.0006
Title (croatian): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Leader: Stipan Jonjić
Jurisdiction: eu
ProjectNumber: N/A
Title (croatian): Centar izvrsnosti za virusnu imunologiju i cjepiva
Title (english): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Acronym: CERVirVac
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZCI
Document URLhttps://www.mdpi.com/2076-393X/10/2/153
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-03-16 22:35:20